香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 中國生物製藥有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事會（「董事會」）宣佈，本集團全 資附屬公司禮新醫藥科技（上海）有限公司（「禮新醫藥」）自主研發的創新藥LM-302「CLDN18.2 ADC」 已被中國國家藥品監督管理局藥品審評中心(CDE)納入突破性治療藥物程序(BTD)，用於聯合PD-1單 抗一線治療CLDN18.2陽性的局部晚期或轉移性胃及胃食管交界部腺癌。 LM-302是一款潛在同類首創(first-in-class)的靶向CLDN18.2的抗體偶聯藥物(ADC)，已在胃癌、胰腺 癌和膽道癌患者中觀察到臨床療效，且Claudin 18.2低表達和PD-L1低表達的患者也有臨床獲益。 2025年美國臨床腫瘤學會(ASCO)年會上，禮新醫藥公布了LM-302聯合PD-1單抗治療胃癌的最新研 究數據：在41例療效可評估的患者中，ORR為65.9%，DCR為85.4%。CLDN18.2 ...

Group 1 - Citigroup gives a "Buy" rating to China Biologic Products with a target price raised to HKD 10.5, expecting over 19 new products to be approved in the next three years, many with sales potential exceeding HKD 20 billion [1] - CMB International maintains a "Buy" rating for Sea Group, raising the target price to HKD 28, citing significant profit growth and improved profitability due to strong volume and price increases in the first half of the year [4] - CITIC Securities maintains a "Buy" rating for JD Health, highlighting strong sales growth in pharmaceuticals and health products, and the efficiency improvements from AI medical applications [2] Group 2 - CITIC Securities maintains a "Buy" rating for Netease-S, raising the target price to HKD 240, driven by steady growth in gaming revenue and expectations of new game launches boosting future income [3] - CITIC Securities maintains a "Buy" rating for Leap Motor, raising the target price to HKD 89.2, with expectations of accelerated new car cycles leading to sustained sales and profit growth [5] - CITIC Securities maintains a "Buy" rating for Xtep International, noting robust growth driven by e-commerce and double-digit growth in same-store sales for its subsidiary [6] Group 3 - CICC maintains an "Outperform" rating for Standard Chartered Group, with second-quarter results exceeding expectations, particularly in non-interest income and wealth management [7] - Huaxing Securities maintains a "Buy" rating for Tencent Holdings, raising the target price to HKD 685, citing strong performance across all business segments, particularly in AI-driven advertising revenue [8]

Core Viewpoint - The Hong Kong stock market for innovative drugs experienced a notable pullback, with the Hong Kong Innovative Drug ETF (520880) declining by 2.6% on August 19, despite a positive sentiment indicated by a real-time premium rate of 0.28% [1][3]. Group 1: Company Performance - China National Pharmaceutical Group reported a revenue of 17.57 billion yuan and a net profit of 3.39 billion yuan for the first half of the year, reflecting year-on-year growth of 10.7% and 140.2% respectively, marking three consecutive reporting periods of double-digit stable growth [3]. - The strong performance of China National Pharmaceutical Group was attributed to better-than-expected revenue growth from innovative products and dividend income [3]. Group 2: Market Trends - As of August 18, the Hong Kong Innovative Drug ETF (520880) tracked the Hang Seng Hong Kong Innovative Drug Selected Index, which has seen a year-to-date increase of 112.33%, significantly outperforming the Hang Seng Index (23.50%) and the Hang Seng Technology Index (22.05%) by 86.82 and 87.46 percentage points respectively [3]. - The adjustment in the market is viewed as a technical correction following a rapid increase, with long-term support expected from domestic policy and overseas value recognition for Chinese innovative drugs [3][6]. Group 3: Industry Outlook - The innovative drug industry is anticipated to undergo a value reassessment, supported by national policy and a clear trend of industry development and upgrading [5][6]. - The innovative drug sector is entering a 2.0 era, with domestic products gradually transitioning from following to leading innovation, benefiting from a favorable environment including engineer advantages, rich clinical resources, and supportive policies [6]. - The Hong Kong Innovative Drug ETF (520880) is the first ETF to passively track the Hang Seng Hong Kong Innovative Drug Selected Index, focusing on the innovative drug industry chain with a high concentration of leading stocks [6].

Core Viewpoint - The recent decline in the innovative drug ETF (159622) is seen as a short-term correction, with expectations of continued growth driven by liquidity and upcoming catalysts such as potential interest rate cuts by the Federal Reserve [1][2][3] Group 1: Market Performance - The innovative drug ETF experienced a decline of over 1.5%, with significant stock performance divergence among its components, including gains from companies like Ganli Pharmaceutical (+7%) and Enhua Pharmaceutical (+5%) [1] - The overall market sentiment remains bullish, with a strong rotation and inflow of capital into innovative drug ETFs during corrections [1] Group 2: Catalysts for Growth - The innovative drug sector is expected to benefit from a liquidity-driven market, particularly with anticipated interest rate cuts from the Federal Reserve, which would lower financing costs for drug companies [1][2] - The sector has seen over $2.5 billion in upfront payments for external licensing agreements in the first half of the year, indicating strong ongoing interest and potential for future growth [2] Group 3: Policy Support - Recent updates from the National Healthcare Security Administration regarding the 2025 national medical insurance drug list and commercial insurance innovative drug list show strong support for innovative drugs, including CAR-T therapies and other cancer treatments [3] Group 4: Future Outlook - The upcoming global pharmaceutical conferences and the expected release of key clinical data are anticipated to provide further momentum for the innovative drug sector [5] - The potential for continued high levels of external licensing agreements and the expiration of patents for significant drugs by 2030 suggest a robust pipeline for Chinese innovative drugs [2][5]

Group 1 - The core viewpoint of the news is that Hong Kong's innovative pharmaceutical stocks experienced a decline, with notable drops in companies such as China Biologic Products, which fell over 7%, and others like Innovent Biologics, WuXi Biologics, and 3SBio, which dropped over 4% [1] - Several Hong Kong innovative pharmaceutical ETFs also saw a decline of approximately 3% due to market influences [1] Group 2 - Specific ETF performance includes: - Hong Kong Innovative Pharmaceutical ETF Fund (520700) at 1.859, down 3.03% - Hong Kong Innovative Pharmaceutical 50 ETF (513780) at 1.920, down 2.98% - Hong Kong Innovative Pharmaceutical ETF (520880) at 1.272, down 2.90% - Other ETFs also reported declines ranging from 2.55% to 2.98% [2] - Analysts noted that multinational pharmaceutical companies have significantly increased their procurement of innovative drug patents in China this year, with procurement amounts from January to May nearing the total expected for 2024, indicating the competitiveness of China's innovative drugs in the international market [2]

Group 1: Market Overview - The Hang Seng Index rose by 0.19%, gaining 48 points to close at 25,224 points, while the Hang Seng Tech Index increased by 0.10% [1] - Early trading volume in Hong Kong stocks reached 135.9 billion HKD [1] Group 2: Company Performances - Tianfeng Securities predicts rapid development of AI applications in the first half of 2025, with strong performance in the AI application sector [1] - Xueqiu (粉笔) saw an 18% increase, while Huoliang Technology (汇量科技) rose over 12%, and Weimeng Group (微盟集团) increased by 8% [1] - Huoliang Technology (01860) is set to announce its earnings at the end of this month, with Mintegral identified as the company's core growth engine [2] - Saijing Technology (赛晶科技) increased by 9% ahead of its earnings release this Friday, with expected mid-term net profit growth of over 167% year-on-year [3] - DeXiang Shipping (德翔海运) rose over 6%, anticipating a mid-term net profit increase of at least 220% [4] - China Rare Earth Holdings (中国罕王) increased by over 11%, reporting over 10% revenue growth in the first half and announcing plans to spin off its gold business for a Hong Kong listing [5] - Zhihu-W (知乎-W) surged over 17%, with plans to announce earnings next Wednesday and receiving continuous investments from long-term fund Fidelity International [6] - Dongfang Zhenxuan (东方甄选) rose over 10%, with a cumulative increase of over 300% since early July, attracting market attention for its "Sam's Club model" [7] - Baixin An-B (百心安-B) saw a peak increase of over 15%, closing with a gain of over 50% after RDN was included in the U.S. hypertension guidelines [8] - Wanwuyun (万物云) increased by over 13%, reporting a 3.88% year-on-year growth in net profit for the first half and a mid-term dividend of 0.951 HKD [9] - BYD Electronics (比亚迪电子) fell over 4%, with institutions citing potential sales drag in consumer electronics due to industry competition [9] - China National Pharmaceutical Group (中生制药) saw a post-earnings decline of over 6%, despite exceeding expectations in innovative product revenue growth and reporting over 10% year-on-year revenue growth [9]

Market Performance - A-shares reached a new high with a trading volume exceeding 28 trillion yuan, with the Shanghai Composite Index up 0.85% at 3728.03 points[1] - The Shenzhen Component Index rose 1.73%, and the ChiNext Index increased by 2.84%[1] - Hong Kong's Hang Seng Index fell 0.37% to 25176.85 points, while the Hang Seng Tech Index gained 0.65%[1] Economic Policy and Market Stability - Chinese Premier Li Qiang emphasized the need for targeted and effective policies to stabilize market expectations and respond to market concerns[1] - The focus is on enhancing service consumption and stabilizing employment to support economic recovery[11] International Relations and Market Impact - Discussions for a trilateral meeting involving the U.S., Russia, and Ukraine are underway, following positive talks between Trump and Zelensky[1] - The geopolitical situation continues to influence market dynamics, with mixed performances in U.S. and European indices[1] Corporate Developments - Anker Innovations is considering a Hong Kong IPO, aiming to raise approximately $500 million (about 3.9 billion HKD) after a 50% increase in stock price this year[10] - Klook is also planning a U.S. IPO with a target of raising $500 million (about 3.9 billion HKD)[10] Sector Performance - The consumer electronics sector showed strong performance, particularly in AI infrastructure, while healthcare and paper industries remained resilient[1] - The energy storage company, DSD, is set to launch an IPO with a target of raising approximately 7.56 billion yuan, focusing on expanding its lithium-ion battery production[10]

Core Viewpoint - China Biologic Products (1177.HK) experienced a significant intraday drop of over 6%, trading at HKD 7.4, with a notable trading volume of nearly HKD 1.3 billion, indicating increased market activity [1] Financial Performance - The company reported a revenue of RMB 17.575 billion for its continuing operations in the first half of the year, representing a year-on-year increase of 10.71% [1] - The gross profit margin stood at 82.5%, reflecting a 0.4 percentage point increase [1] - Shareholder profit reached RMB 3.389 billion, marking a year-on-year growth of 12.31% [1] - Earnings per share were reported at RMB 0.1882, with an interim dividend of HKD 0.05 declared [1] Product Development - In the first half of the year, the company received NMPA approval for two innovative products, Putanling and Anqixin [1] - Revenue from innovative products amounted to RMB 7.8 billion, showing a year-on-year increase of 27.2% [1] - Additionally, five generic drugs received NMPA approval, contributing to positive growth in overall generic drug revenue during the same period [1]

中国生物制药(01177)发布公告，该公司将于2025年9月23日派发中期股息每股0.05港元。 ...

Group 1: Market Overview - The Hang Seng Index rose by 0.19%, gaining 48 points to close at 25,224 points, while the Hang Seng Tech Index increased by 0.10%. The early trading volume in the Hong Kong stock market reached HKD 135.9 billion [1] Group 2: AI Application Sector - The AI application sector is experiencing rapid growth, with companies like Fenbi (02469) rising by 18%, Huilyang Technology (01860) increasing over 12%, and Weimob Group (02013) up by 8% [1] Group 3: Earnings Reports and Expectations - Huilyang Technology (01860) is set to announce its earnings at the end of the month, with Mintegral identified as the core growth engine for the company [1] - Sijingt Technology (00580) is expected to report a more than 167% year-on-year increase in mid-term net profit this Friday [1] - DeXiang Shipping (02510) anticipates at least a 220% growth in mid-term net profit, with earnings report scheduled for next Monday [2] - China Rare Earth Holdings (03788) reported over 10% revenue growth in the first half and announced plans to spin off its gold business for a Hong Kong listing [3] - Zhihu-W (02390) is expected to release its earnings next Wednesday, with significant investment from long-term fund Fidelity International [4] - Dongfang Zhenxuan (01797) has seen its stock price increase over 300% since early July, drawing market attention for its "Sam's Club model" [5] - Baixin An-B (02185) saw a significant rise, with a 50% increase yesterday, as RDN was included in the U.S. hypertension guidelines [6] - Wanwuyun (02602) reported a 3.88% year-on-year increase in net profit for the first half, with an interim dividend of HKD 0.951 [7] Group 4: Company Performance - BYD Electronics (00285) experienced a decline of over 4%, attributed to competitive pressures affecting sales of consumer electronics [8] - China National Pharmaceutical Group (01177) saw a drop of over 6% post-earnings, despite exceeding expectations for revenue growth of over 10% in the first half [9]